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ductivity and daily activities was assessed at study baseline, using the validated 
arthritis-specific Work Productivity Survey (WPS). Results: At baseline, pts had a 
mean age of 48 years and 55% were female; 61.6% had psoriasis skin involvement 
≥ 3% body surface area. 59.5% of pts were employed, 14.0% work disabled due to 
PsA, and 13.5% retired. Overall, a high burden of PsA on workplace and household 
productivity and on social activities was reported, with on average > 1 week (wk) of 
paid work affected and > 2 wks of household duties or social activities affected per 
month. Household productivity losses were on average, up to 2 to 3 times higher in 
non-employed or disease work disabled pts vs employed pts: on average household 
duties were affected 18 days or 26 days vs 10 days/month, respectively. Employed pts 
with manual jobs reported higher productivity losses at work and within the home 
vs those with non-manual jobs. Overall, 41.8% of pts required regular assistance 
from relatives, friends or paid caregivers in their usual activities because of PsA. 
These pts reported on average 2 to 3 times higher workplace and household produc-
tivity losses vs pts who did not require help. ConClusions: PsA is associated with 
a high burden of disease on workplace and household productivity that could lead 
to large financial burden for pts and society. Effective PsA treatments are needed 
to prevent disability and work losses, and reduce economic burden of the disease.
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objeCtives: To estimate the economic burden of axial spondyloarthritis (axSpA) and 
directly compare ankylosing spondylitis (AS) and axSpA with no definitive sacroiliitis 
on X-ray (non-radiographic axSpA, nr-axSpA) in terms of workplace and household 
productivity losses. Methods: The ongoing Phase 3 RAPID-axSpA trial (NCT01087762) 
recruited patients (pts) with adult-onset active axSpA according to ASAS criteria, and 
included AS and nr-axSpA pts. The impact of axSpA on workplace and household 
productivity was assessed at study baseline (BL), using the arthritis-specific Work 
Productivity Survey (WPS). Results: At BL, 69.2% of axSpA, 67.4% AS and 71.4% nr-
axSpA pts were employed outside the home. A high burden of axSpA on workplace and 
household productivity and on social activities was reported, with slightly higher burden 
in nr-axSpA vs AS pts. More AS vs nr-axSpA pts were unable to work (15.7% vs 8.2%). On 
average, axSpA pts reported > 1 wk of paid work and > 2 wks of household duties or social 
activities affected/month. Household productivity losses were up to 2–3 times higher in 
non-employed and disease work disabled vs employed pts. Employed pts with manual 
jobs reported higher losses at paid work and within household vs pts with non-manual 
jobs. 39.1% of axSpA pts required regular assistance in their usual activities (42.1% in 
AS vs. 35.4% in nr-axSpA) and reported higher workplace and household productivity 
losses vs those who did not require help. Similar patterns were observed in AS and nr-
axSpA. ConClusions: A similarly high burden of disease on workplace and household 
productivity was seen in AS and nr-axSpA pts that could lead to large financial burden 
for pts and society. Effective axSpA treatments are needed to prevent disability and work 
losses and to reduce the economic burden of axSpA.
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objeCtives: To assess loss of paid productivity in Polish rheumatoid arthritis (RA) 
patients according to disease activity and disability. Methods: We conducted a 
prospective one-center observational study with 6-month time horizon. The sample 
consisted of 109 RA patients of working age (women:< 60 years; men:< 65 years), 
stratified according to Disease Activity Score (DAS28-CRP) and disability index of 
the Health Assessment Questionnaire (HAQ-DI). Productivity loss was expressed 
by absenteeism and employment status changes: reduced work hours (part-time), 
unemployed and/or early retirement due to RA. Spearman rang correlation coef-
ficient test was used to investigate the relationship of productivity loss with disease 
activity and disability. Results: Patients were on average 48.5 years of age, had a 
mean disease duration of 8.5 years, and 85% were female. DAS28-CRP was ≤ 5.1 in 
52 patients (group A) and > 5.1 in 57 patients (group B). HAQ-DI was > 2 in 22 patients 
(group I), > 1 and ≤ 2 in 54 patients (group II), ≤ 1 in 33 patients (group III). Number of 
patients who lost productivity was 94 (86%) (79% in A vs. 93% in B, 100%, 94% and 
63.6% in I, II and III, respectively). Of them 63 (58%) patients received disability pen-
sion due to RA (48% in A vs. 67% in B, 77%, 76% and 15% in I, II and III, respectively). 
Mean number of working days lost was 120.7 (97.2 in A vs. 142.9 in B; 157.3, 143.1 
and 59.8 in I, II and III, respectively). Proportion of patients with productivity loss 
and number of working days lost were correlated with disease activity (p< 0.01 
and p< 0.001, respectively) and disability index (both p< 0.001). ConClusions: This 
study indicates high impact of disease activity and disability on productivity loss 
in RA patients. Treatment aiming at reducing disease activity decreases disability 
progress and may enhance productivity in Polish patients with RA.
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objeCtives: To assess transportation needs and number of home visits in rela-
tion to disease activity (DAS-28CRP) and disability index of the Health Assessment 
Questionnaire (HAQ-DI) in Polish patients with rheumatoid arthritis (RA) Methods: 
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objeCtives: Until recently, large-scale head-to-head randomized clinical trials (RCT) 
involving biologic drugs in the treatment of rheumatoid arthritis (RA) have been lack-
ing. In addition, most evidence of biologic RA treatments has relied on combination 
treatment with methotrexate. The RCT ADACTA compared adalimumab vs. tocili-
zumab monotherapies as the 1st biologic treatments for severe RA, and demonstrated 
tozilizumab’s clinical superiority over adalimumab. Based on this evidence, we assess 
the cost-utility of adalimumab and tocilizumab monotherapy in RA after the failure 
of traditional disease modifying antirheumatic drug(s) (tDMARD). Methods: Two 
sequences, namely adalimumab or tocilizumab followed by etanercept followed by 
best supportive care (BSC) including tDMARDs, were implemented in a probabilistic, 
individual sampling (microsimulation model) setting in order to compare the results 
among 1,230 Finnish RA patients in a lifetime scenario (based on the Finnish social 
insurance institution reimbursement data, 1,230 [42.6%] of anti-TNF users purchased 
anti-TNF without tDMARD in 2012). Clinical outcomes (no ACR20, ACR20, ACR50 and 
ACR70 responses, and their impact on Health Assessment Questionnaire, HAQ) were 
obtained from ADACTA and drug survivals from literature. HAQ-scores were linked 
non-linearly to EQ-5D scores based on the tocilizumab trials, and to hospitaliza-
tions and lost production days through literature data. All resources were valued 
with Finnish unit costs (drugs 4/2013, other costs 2012 real value). Analyses were 
performed from the Finnish payer perspective (excluding productivity loss) and 
societal perspective including 3% annual discount rate. Results: A QALY gained 
with the tocilizumab sequence costs € 14,294 (€ 9,111) compared with the adalimumab 
sequence from the payer (societal) perspective. The respective expected value of per-
fect information (EVPI) for the payer was € 996/patient. Population EVPI was € 121,770 
with € 20,000/QALY gained. According to cost-effectiveness acceptability frontier, the 
tocilizumab sequence had 89% probability for cost-effectiveness at € 20,000/QALY 
gained. ConClusions: After tDMARD(s) failure, tocilizumab monotherapy was cost-
effective in comparison to adalimumab monotherapy.
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objeCtives: Poor information on long term outcomes and costs on Tumor Necrosis 
Factor-α (TNF-α ) inhibitors in Psoriatic Arthritis (PsA) are available. Our aim was 
to evaluate long-term costs, benefits and cost-effectiveness of TNF-α inhibitors in 
PsA patients with inadequate response to conventional treatment with traditional 
disease-modifying antirheumatic drugs (DMARDs). Methods: A total of 55 of the 
107 enrolled patients included in the study at one year, completed the 5 years follow 
up period (2005-2010). Patients aged older than 18 years, with different forms of PsA 
and failure or intolerance to DMARDs therapy were treated with anti-TNF agents. 
Information on resource use, quality of life, disease activity, function and laboratory 
values were collected at baseline and through the 5 years of therapy. Costs (expressed 
in Euro 2011) and utility (measured by EQ-5D instrument) before and after TNF-α 
inhibitorstherapy were compared in order to estimate the incremental cost per qual-
ity adjusted life year (QALY) gained. The cost-effectiveness acceptability-curve was 
also calculated. Results: Thirty-four patients were males (61.8%), aged mean(SD)= 
48.94(11.09) years. The majority of patients (83.6%) had a predominant or exclusive 
peripheral arthritis. At the end of the 5 years, there was a significant increase in direct 
costs due to an increase of drug cost caused by TNF-α inhibitors that was partially 
offset by the decrease in indirect costs. The incremental cost estimated and the util-
ity gained of 0.22 gave an incremental cost-effectiveness ratio of 39,678.6 € per QALY 
gained for the society. The acceptability curve showed there would be a 90% likeli-
hood that anti-TNF therapy would be considered cost-effective at willingness-to-pay 
threshold of € 60,000 per QALY gained. ConClusions: Cost-effectiveness ratios are 
within the commonly accepted Italian willingness-to-pay threshold. These results 
show how TNF-α inhibitors could be long-term cost-effectiveness treatment. Our 
results need to be confirmed in larger samples of patients.
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objeCtives: To estimate the economic burden of moderate to severe psoriatic 
arthritis (PsA) on workplace and household productivity using data from RAPID-
PsA. Methods: The ongoing Phase 3 RAPID-PsA trial (NCT01087788) recruited 
patients (pts) with active PsA. Impact of PsA on workplace and household pro-
